MedTrace Logo

Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy

NCT04124510 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2021-01-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of the Asthma improvement of Flutiform K-haler after 12 weeks of treatment in patients with moderate to severe uncontrolled\* asthma following mid-dose ICS/LABA DPI therapy.

Conditions

Interventions

DRUG

Brand Name: Flutiform K-haler

Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation

Sponsors & Collaborators

  • Mundipharma Korea Ltd

    lead INDUSTRY

Principal Investigators

  • Kwang Ha Yoo · Konkuk University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-26
Primary Completion
2020-09-14
Completion
2020-09-14

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04124510 on ClinicalTrials.gov